Hall Laurie J Trustee Grows Stock Holdings in Relx Plc $RELX

Key Points

• Hall Laurie J Trustee increased its shares in Relx Plc by 23.6%, now holding a total of 84,930 shares valued at approximately $4.28 million.
• Several institutional investors, including Ameriprise Financial Inc. and Bank of America Corp DE, also raised their stakes in Relx, indicating a growing interest in the company's stock.
• Relx's stock has been rated as a Buy by analysts, with one even giving it a Strong Buy rating amidst recent changes, including a cut in its dividend payment.

Hall Laurie J Trustee boosted its holdings in Relx Plc (NYSE:RELX - Free Report) by 23.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 84,930 shares of the technology company's stock after acquiring an additional 16,190 shares during the quarter. Relx accounts for approximately 1.5% of Hall Laurie J Trustee's investment portfolio, making the stock its 24th biggest holding. Hall Laurie J Trustee's holdings in Relx were worth $4,281,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in RELX. Ameriprise Financial Inc. lifted its position in Relx by 368.7% in the 4th quarter. Ameriprise Financial Inc. now owns 2,807,038 shares of the technology company's stock valued at $127,437,000 after acquiring an additional 2,208,119 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Relx by 9.3% during the 4th quarter. BNP Paribas Financial Markets now owns 46,198 shares of the technology company's stock worth $2,098,000 after buying an additional 3,917 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Relx by 4.2% during the 4th quarter. Bank of America Corp DE now owns 6,246,462 shares of the technology company's stock worth $283,714,000 after buying an additional 253,107 shares in the last quarter. Balyasny Asset Management L.P. lifted its position in shares of Relx by 32.6% during the 4th quarter. Balyasny Asset Management L.P. now owns 58,235 shares of the technology company's stock worth $2,645,000 after buying an additional 14,327 shares in the last quarter. Finally, Baird Financial Group Inc. bought a new position in shares of Relx during the 4th quarter worth approximately $623,000. Institutional investors own 15.02% of the company's stock.

Relx Stock Performance

Shares of Relx stock traded up $0.33 during mid-day trading on Monday, hitting $47.38. 1,196,917 shares of the stock were exchanged, compared to its average volume of 922,388. The company has a 50-day simple moving average of $50.49 and a 200 day simple moving average of $51.22. The company has a debt-to-equity ratio of 2.55, a quick ratio of 0.42 and a current ratio of 0.47. Relx Plc has a 12 month low of $44.19 and a 12 month high of $56.33. The company has a market capitalization of $86.91 billion, a P/E ratio of 25.47, a P/E/G ratio of 3.07 and a beta of 0.87.

Relx Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, September 16th. Stockholders of record on Friday, August 8th will be paid a dividend of $0.2634 per share. The ex-dividend date is Friday, August 8th. This represents a dividend yield of 170.0%. Relx's dividend payout ratio (DPR) is presently 28.49%.

Analysts Set New Price Targets

Separately, Wall Street Zen cut shares of Relx from a "buy" rating to a "hold" rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy".

Relx Company Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.